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Abstract
Background: Urotensin II (UII) is a potent vasoconstrictor peptide, which signals through a G-protein coupled receptor
(GPCR) known as GPR14 or urotensin receptor (UTR). UII exerts a broad spectrum of actions in several systems such as
vascular cell, heart muscle or pancreas, where it inhibits insulin release.
Objective: Given the reported role of UII in insulin secretion, we have performed a genetic association analysis of the UTS2
gene and flanking regions with biochemical parameters related to insulin resistance (fasting glucose, glucose 2 hours after a
glucose overload, fasting insulin and insulin resistance estimated as HOMA).
Results and Conclusions: We have identified several polymorphisms associated with the analysed clinical traits, not only at
the UTS2 gene, but also in thePER3 gene, located upstream from UTS2. Our results are compatible with a role for UII in
glucose homeostasis and diabetes although we cannot rule out the possibility that PER3 gene may underlie the reported
associations.
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Introduction
Urotensin II (UII) is a cyclic undecapeptide that was initially
isolated from fish urophysis and subsequently discovered in
mammals including humans [1]. UII is considered the most
potent endogenous vasoconstrictor discovered to date. It binds to a
G-protein coupled receptor (GPCR) known as GPR14 or
urotensin receptor (UTR) [2], which is widely expressed in
cardiovascular, pulmonary, central nervous, renal and metabolic
systems. UII has emerged as a contributor to cardiovascular
physiopathology [3,4].
The UTS2 gene, encodes UII and is located at 1p36.23. There are
three different UII preproteins encoded by three different transcripts
(Figure 1). In accordance with the University of Santa Cruz Genome
Browser (http://genome.ucsc.edu/cgi-bin/hgGateway), two of them,
named UCSC uc001aos.2 and uc001aor.2, are short mRNA
transcripts of 5.8 Kb and 5.5 kb respectively encoding two
preproteins of 139 and 124 aminoacids that differ in the amino-
terminal end. The third one, called uc001aoq.2, is a longer
transcript of about 70 kb that has been identified in pancreas and
spleen libraries. It codes for a preproprotein isoform of 139
aminoacids with the same amino-terminal end of the uc001aor.2
transcript and a different carboxi-terminal end. The mature
peptide, with only 11 aminoacids, exerts a broad spectrum of
actions in several systems through UTR binding. UII promotes cell
proliferation of vascular and cancer cells, has inotropic and
hypertrophic effects on heart muscle, modulates glomerular
filtration and release of catecholamines in the kidney [5]. UII is
also present in the pancreas where inhibits insulin release [6,7].
Elevated plasma levels of UII and increased UII expression have
been evidenced in numerous diseased conditions, including
hypertension, atherosclerosis, heart failure, pulmonary hyperten-
sion, diabetes, renal failure, and the metabolic syndrome [8].
Several polymorphisms at the UTS2 gene have been associated
with type 2 diabetes mellitus (T2DM) [9-13], insulin resistance
[14] and diabetic complications such us diabetic retinopathy and
carotid atherosclerosis [15]. The UTS2 gene regulates fat
accumulation in skeletal muscle and fatty acid metabolism, two
biological pathways related to T2DM in humans [16]. UTS2
polymorphisms have also been associated with essential hyperten-
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sion [17]. Finally, UTS2 gene polymorphisms are associated with
myocardial infarction in individuals with and without metabolic
syndrome [18,19]. All of these associations have been described in
Asian populations.
This study is aimed at investigating the implication of UTS2
gene variants in several traits related to T2DM in the Spanish
population. For this purpose, we have extracted genotypic data at
the UTS2 gene region from a GWAS recently performed in a
Spanish population-based sample [20].
Results
We have analysed for association with fasting glucose, 2 h-
glucose, insulin and HOMA, the region of chromosome 1 from
7,711,426 to 8,168,634 bp, including 97 polymorphisms and seven
genes: CAMTA1, VAMP3, PER3, UTS2, TNFRSF9, PARK7
andERRFI1.Regarding the UTS2 region, only one of the SNPs
analysed, namely rs228652, is located in the chromosomal region
shared by the three UTS2 transcripts. The remaining 21
polymorphisms are located at the region coding for the longest
mRNA (uc001aoq.2). Figure 1A shows the genomic organisation
in this region.
We have detected several associations for all the phenotypes
analysed (Tables S1, S2, S3, S4). These associations are confined
to the LD block of UTS2 gene at the adjacent one upstream (D9
between blocks 0.75) (Figure 1B). It is interesting to note that none
of them is downstream the LD decay observed at the 39 end of the
region encoding the longest transcript (Figure 1C–D).
For fasting glucose, most of significance is confined to the PER3
gene, the adjacent one upstream UTS2. Two SNPs in the UTS2
region are also associated with glucose levels (rs17374781 and
rs665244). A similar situation occurs in the test for association with
HOMA, where most of associated SNPs lie within PER3 region
and only two (rs504560 and rs500508) are in the UTS2 region.
Fasting insulin is the phenotype for which less associated SNPs
have been found and all of them are located at PER3 gene. For
2 h-glucose, the pattern of association is slightly different, since we
cannot observe a cluster of associated SNPs at the UTS2 gene
region.
Haplotypic analysis
In order to clarify if observed associations could be related to
UTS2 locus, we performed a haplotype analysis at this candidate
region (Table 1). With this purpose, we selected tagging SNPs.
Haplotypes with a population frequency (MHF) under 5% were
rejected.
We first selected tagging SNPs for the whole region (from
CAMTA1 to ERRFI1). We selected 25 SNPs that determine 557
possible haplotypes, only 3 with a MHF.5%. No overall
significance was observed (data not shown).
We next restricted the selection of tagging SNPs to the PER3-
UTS2 region. We analysed 14 tagging SNPs that form 224
possible haplotypes, 5 of them with MHF.5%. These haplotypes
were associated with fasting insulin (F = 2.91, df = 4, p = 0.021)
and HOMA (F = 3.32, df = 4, p = 0.011). For fasting glucose, only
a trend for association was observed (F = 2.34, df = 4, p = 0.054).
To further narrow the most associated chromosomal region, we
analysed independently PER3 and UTS2 regions. For PER3, 7
tagging polymorphisms determine 5 common haplotypes that
modulate fasting insulin (F = 3.79, df = 4, p = 0.0047) and HOMA
values (F = 3.05, df = 4, p = 0.017). For UTS2, 9 SNPs were
selected to conform 6 common haplotypes; these haplotypes are
strongly associated with fasting glucose values (F = 3.1, df = 5,
p = 0.008) and show a trend for fasting insulin values (F = 2.02,
df = 5, p = 0.074). In order to assess the independence of these
observations, we analysed both regions in a single regression
model in which haplotypes at one of the loci are tested for
association with the study phenotypes entering the tagging SNPs of
the others loci as covariates in the model. As expected, controlling
one locus by the effect of the other locus, all associations are lost
(0.176#p#0.945) indicating that the observed associations at both
loci are not independent and that they are tracking the same
disease allele.
Discussion
In this report, we have analysed the chromosomal region
encoding UTS26200 kb. Genotypic data derived from a 250 k
Affymetrix GWAS in our population was combined with Hapmap
data to increase the density of SNPs in the region through
imputation. To our knowledge, this is the first time that UTS2 is
analysed for association with T2DM related traits in a European
population. In the monogenic analysis, positive signals are
scattered over PER3 and UTS2 gene regions. The joint analysis
of both genes by means of tagging SNPs and haplotypic
association analyses showed a modest association for insulin and
HOMA, although for glucose values we only observed a trend
toward association. Analysing both genes independently we found
that PER3 region is strongly associated with fasting insulin and
UTS2 with fasting glucose. However, the integration of both
regions in a single model in which the effect of one of them is
controlled for the effect of the other region indicates that the
observed associations at both loci are not independent, but they
are related to the same causal site.
Previous studies have associated the UTS2 gene variants with
T2DM traits. The 143G.A (rs228648) was associated with
T2DM in Chinese [9,13] and the 3836C.T (S89A, rs2890565)
with insulin levels and T2DM in Japanese [10,11]. In the report by
Ong et al. in Hong Kong Chinese population [14], these two
polymorphisms and the promoter SNP 2605G.A (rs228647)
were associated with insulin resistance estimated as HOMA. The
study of Ong et al. [14] is the first to analyse and associate a
promoter polymorphism with T2DM related traits and also the
first to construct haplotypes at the UTS2 gene region; they found
that carriers of the three-loci haplotype GGT made up of 2605G,
143G and 3836T had higher plasma levels of UII, fasting plasma
insulin, HOMA-IR and pancreatic b-cell function estimated as
HOMA-b%.
In our study, we have a poor coverage of the UTS2 region
coding for the two short transcripts. The rs228652 analysed by our
group is located only 849 bp from the S89A polymorphism
(D9= 0.77) but it is not associated with any of the traits analysed in
our population. By contrast, we have extended our study to UTS2
region encoding the long transcript and flanking regions and have
found that the region associated with T2DM related traits exceeds
the UTS2 region and include the PER3 gene. PER3 is one of the
period clock genes implicated in the circadian clock function.
Alterations of the internal clock function is related to the
Figure 1. The UTS2 gene region. A. University of Santa Cruz (UCSC) gene region map. B. Linkage disequilibrium map. C, D, E, F. Graphical
representation of the association analysis of the UTS2 gene region with fasting glucose (C), 2 h-glucose (D), fasting insulin (E) and HOMA (F). Dots
symbolize the logarithm of the p value at each marker.
doi:10.1371/journal.pone.0019327.g001
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development of obesity and other metabolic age-related diseases,
including abnormal glucose metabolism [21]. PER3 mRNA levels
have been shown to be lower in T2DM subjects and to negatively
correlate with glycosylated haemoglobin and fasting glucose levels
[22,23]. In addition, a polymorphic 54-bp repeat length variant
was associated with higher serum levels of IGF-I and IGF-I to
IGFBP3 ratios [24]. This polymorphism has also been associated
with IL-6 serum levels [25]. IL-6 is an adipokine, a class of
cytokine which includes molecules such as TNFa or PAI that play
a central role in body homeostasis, including the regulation of food
intake and energy balance, insulin action, lipid and glucose
metabolism, angiogenesis and vascular remodelling, regulation of
blood pressure and coagulation. Moreover, downstream UTS2 is
located in the TNFRSF9 gene, which encodes a receptor for
tumor necrosis factor (TNF), another adipokine. Three polymor-
phisms within the coding region of TNFRSF9 (namely rs161827,
rs161811 and rs519546) have been shown to modulate UTS2 gene
expression, as revealed by the use of the mRNA by SNP Browser
1.0.1. (http://www.sph.umich.edu/csg/liang/asthma/) [26,27].
In our analysis, we have only included two polymorphisms at
the TNFRSF9 gene region (rs2453021 and rs863171) that are not
associated with any of the traits analysed. These two SNPs are in
the same block of UTS2 and the three polymorphisms that
modulate UTS2 mRNA levels.
The role of UII in glucose homeostasis is well established.
Plasma UII levels have been reported to be almost twice as high in
diabetic patients compared with healthy subjects [28]. This
increase in UII level does not seem to be a consequence of
hyperglycemia, but UII itself may be responsible for hyperglyce-
mia. UII and the UTR are both expressed in the pancreatic islets,
where it inhibits insulin release without affecting glucagon or
somatostatin levels [6,7]. A recent report has, however, suggested
that inhibition of glucose-induced insulin secretion in beta cells is
mediated by the UII receptor and PKC pathway, as well as the
somatostatin receptor, which could be activated by high dose of
UII [29]. Other proposed mechanisms include activation of L-type
Ca2+ channels, increase in the phospholipid turnover, activation of
the adenylate cyclase/cAMP system (GLP-1) or blockage of ATP-
dependent K+ channels [30]. In cardiomyocytes, UII also
increases phosphorylation of Akt and its downstream target
Table 1. Haplotypic analysis.
HAPLO FREQ BETA(A) GLC BETA(A) OGTT BETA(A) insul BETA(A) HOMA
GENES: PER3, UTS2
CCCTTGCGACAGCC 0.158 (-ref-) (-ref-) (-ref-) (-ref-)
CTCGTATGGTGGTC 0.0604 20.02054 0.02258 20.02873 20.02133
CTCTCGTAATAATC 0.101 20.035 20.002814 20.1448 20.1575
CCCTTGCGATGGTC 0.109 20.04498 20.07108 20.1303 20.1592
CTCTCGCGATGGTC 0.0628 20.003319 0.02066 0.007429 20.002714
F= 2.34 F = 1.22 F = 2.91 F = 3.32
df = 4, 704 df = 4, 598 df = 4, 598 df = 4, 598
p= 0.0542 p = 0.301 p=0.0212 p=0.0105
SNPs:rs697690,rs227163,rs10462020,rs228682,rs228641,rs1040397,rs504560,rs228703,rs665244,rs2066978,rs2066980,rs228652,rs170631,rs4908486
GENE: UTS2
GCTTCCCGC 0.149 (-ref-) (-ref-) (-ref-) (-ref-)
ATTTTGAGC 0.065 20.03465 20.01244 0.05278 0.03828
GTCTTGCCC 0.116 20.03363 20.02672 20.07208 20.09015
GCTCTCCGC 0.0744 0.007965 20.05835 20.109 20.1114
GCTTTGCGC 0.235 20.02672 20.02313 20.03691 20.05894
ACTTTGACA 0.0615 0.04437 0.05885 20.1732 20.15
F = 3.1 F = 0.971 F = 2.02 F = 1.76
df = 5, 710 df = 5, 602 df = 5, 602 df = 5, 602
p=0.00897 p =0.435 p= 0.0738 p= 0.119
SNPs: rs228724,rs228721,rs1040396,rs665244,rs2066978,rs4908486,rs17374781,rs579992,rs228652
GENE: PER3
CGCATTA 0.374 (-ref-) (-ref-) (-ref-) (-ref-)
CGTGCTA 0.136 20.007949 0.03718 0.108 0.1068
CTTATTT 0.14 20.02031 0.03539 20.07667 20.08529
CTTATTA 0.175 20.01644 0.05486 0.0318 0.01328
GGCACTA 0.0555 0.04007 0.08027 20.1653 20.1447
F= 1.81 F = 1.38 F = 3.79 F = 3.05
df = 4, 708 df = 4, 600 df = 4, 600 df = 4, 600
p= 0.126 p = 0.24 P =0.0047 p=0.0167
SNPs: rs696306,rs12741937,rs10864316,rs228682,rs228664,rs2640909,rs170631
doi:10.1371/journal.pone.0019327.t001
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GSK-3b, a serine/threonine protein kinase discovered for its
property to inhibit glycogen synthase that has been implicated in
many disease states, among others tumorigenesis, diabetes or
neurodegenerative diseases [31]. In salmon, UII increases glucose-
6-phosphatase activity and reduces liver glycogen content [32].
Activation of the UII system was also proposed to be associated
with the development of metabolic syndrome [8]. Although UII
doesn’t seem to be implicated in the initiation of the individual
factors comprising the metabolic syndrome, there is evidence that
UII plays a role in the development of each factor [33]. UII plays a
role in hypertension, in both dyslipidemia and obesity, and in
hyperglycemia [5]. Increased plasma UII levels in patients with
T2DM was recently associated with the metabolic syndrome
phenotype [34]. The primary clinical outcomes of the metabolic
syndrome are cardiovascular diseases, such as coronary heart
diseases or stroke. Several reports have shown that plasma UII
levels are increased in cardiovascular diseases such as congestive
heart failure and other cardiac diseases (for review see Ross et al.
2010 [5]). Expression of both UII and UT receptors are increased
in the heart of patients after myocardial infarction, suggesting a
possible pathological role in cardiac remodeling [35]. Indeed, UII
was shown to be involved in cardiac fibrosis, hypertrophy [35] and
remodeling [36]. Interestingly, several studies have linked
hyperglycaemia, at the time of hospital admission, with higher
mortality in patients with acute coronary syndrome (ACS) [37–
43]. The effect of admission hyperglycaemia on mortality seems to
be independent of a previous diagnosis of diabetes mellitus;
indeed, some studies have suggested that mortality may be higher
in patients with hyperglycaemia without a previous history of
diabetes, compared to those with known history of diabetes
[44,45]. This last study showed that given the same degree of
hyperglycemia on admission, known diabetes has a protective
influence on short-term outcomes in hospitalized ACS patients.
The mechanism by means chronic diabetes mitigates the effect of
hyperglycemia in acute cardiovascular event is unknown.
Given that UII has been proven to be a potent insulinostatic
peptide, urotensin II receptor antagonists have been proposed as
potential drugs for treating the impaired insulin secretion
characteristic of T2DM patients. In a follow-up study, Clozel et
al. observed that chronic oral treatment with palosuran, a potent
and selective UTR antagonist, improved survival, increased
insulin, and slowed the increase in glycemia, glycosylated
hemoglobin, and serum lipids. Furthermore, palosuran increased
renal blood flow and delayed the development of proteinuria and
renal damage [46]. Other authors have reported that, in the
absence of exogenous UII, palosuran potentiated glucose-induced
insulin release in perfused rat pancreas [47] and decreased 24-
hour urinary albumin excretion rate in diabetic patients with renal
failure with regard to their disease progression [48]. However,
other studies have reported that palosuran has no effect on the
first-phase insulin response, insulin secretion and blood glucose
levels during the meal tolerance test or on homeostasis model
assessment-insulin resistance score of diabetic patients in diet-
treated patients with T2DM [49]. Furthermore palosuran did not
affect albuminuria, blood pressure, glomerular filtration rate, or
renal plasma flow significantly in hypertensive patients with type 2
diabetic nephropathy [50].
In conclusion, our results are compatible with a role for UII in
glucose homeostasis and diabetes. Although we have not examined
previously associated polymorphisms such as S89A, we have
studied highly linked SNPs in UTS2 gene region with positive
results. However, we cannot rule out the possibility that PER3
gene underlies the reported associations, although the biological
relevance of PER3 in glucose metabolism is not well established.
Further analysis in independent Caucasian populations and
functional analysis are needed to answer this question.
Methods
Study design
This study comprises 801 non related Caucasian men (n = 433,
54.05%) and women (n = 368, 45.95%) who were recruited by a
simple random sampling approach from a cross-sectional
population-based epidemiological survey in Spain, aimed to
investigate the prevalence of anthropometric and physiological
parameters related to obesity and other components of MS
[51,52]. Participants with previous diagnosis of type 1 diabetes
were excluded from the study.
All participants gave their written consent to participate in the
study. The study protocol was approved by the Ethics Committee
of the Hospital Clı´nico San Carlos of Madrid.
Measurements
Biochemical determinations. After an overnight fasting
period, 20 ml of blood were obtained from an antecubital vein
without compression. Plasma glucose was determined in duplicate
by a glucose-oxidase method adapted to an Autoanalyzer (Hitachi
704, Boehringer Mannheim, Germany). Serum insulin was
determined by RIA (Human Insulin Specific RIA kit, Linco
Research Inc., St Louis MO, USA). Oral glucose tolerance test
(OGTT) using 75 g of glucose was performed according to the
WHO recommendations. Two hours after glucose administration,
blood samples were obtained for the determination of glucose
levels and interpreted the results according to Genuth et al. [53].
The crude prevalences of T2DM, impaired fasting glucose (IFG)
and impaired glucose tolerance (IGT) were respectively 8.7%,
13.6% and 15.0%.
Insulin resistance was estimated by the homeostasis model
assessment (HOMA-IR) method according to the formula: Insulin
(mU/l)6Glucose (mmol/l)/22.5 [54].
Genotypes. Genotypic data were derived from a genome
wide scan performed with the 250 k NspIAffymetrix chip.
Genotyping was done according to manufacturer’s instructions.
A 1% of the samples are duplicated in the study, being the overall
concordance between them throughout the genome in the range
95–98%. After the application of additional genotyping quality
controls (SNPs genotyped in at least 90% of individuals, with
minor allele frequency (MAF)$0.05, and Hardy-Weinberg
equilibrium p.0.05), we performed a genome wide imputation
using MACH 1 software (http://www.sph.umich.edu/csg/
abecasis/MACH) [55] and CEU HapMap phased haplotypic
data (http://www.HapMap.org).
Statistical analysis
From the GWAS data, we extracted the SNPs included in the
region from 7,711,426 to 8,168,634 bp (NCBI37/hg19) of
chromosome 1 (including the largest UTS2 transcript 6200 kb)
(Table S5). A total of 98SNPswere analysed for association with
fasting glucose, 120-min glucose (after an OGTT), fasting insulin
and HOMA, using the linear regression procedure included in the
PLINK software [56]. Phenotypic values were log transformed to
achieve approximately normal distribution. All the studies were
adjusted by sex, age, BMI, smoking (defined as present or past
history of smoking of at least five cigarettes per day for a minimum
of 5 years), alcohol consumption (defined as a daily intake of more
than 1 drink, equivalent to 10 g of pure ethanol), and physical
activity (physical activity was defined as light or moderate activity
Urotensin and Insulin Resistance
PLoS ONE | www.plosone.org 5 April 2011 | Volume 6 | Issue 4 | e19327
for a minimum of 60 minutes per session at least three times a
week). A p value under 0.05 is interpreted as significant.
For the analysis of linkage disequilibrium (LD) patterns and
selection of tagging SNPs we used Haploview software [57].
For haplotypic association analysis, we have also employed
PLINK v1.06 software [56]. Only haplotypes with a population
frequency over 5% were retained for analysis.
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